A ruling in the Supreme Court of the United States (SCOTUS) on Thursday found that foreign law deserves ‘respectful consideration’ but should not determine a class action’s outcome.
In the case, USA-buyers of vitamin C, with the support of the Trump administration and the US Chamber of Commerce, had accused Chinese manufacturers, who have cornered 60% of the worldwide market for the vitamin, of price and supply-fixing in violation of American antitrust laws.
"SCOTUS has thrown a spanner in the works, creating uncertainty, leaving the lower courts to untangle and then apply the nebulous standard"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze